TolDC therapy therefore seems able to adjust the immune system towards autoantigen-specific tolerance in vivo, justifying further clinical testing whether proinsulin-pulsed tolDC induce long-lasting specific immune modulation in T1D patients with remaining beta-cell function, to assess whether these functional beta-cells can be protected from autoimmune destruction. Here, INS is linked to type 1 diabetes mellitus.